Testa, L <br/><br/>
What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel.  [electronic resource] 

 -  QJM : monthly journal of the Association of Physicians  Jun 2010 
 - 367-77 p.  digital 
<br/><br/> Publication Type: Journal Article; Review; Systematic Review 
<br/><br/><label>ISSN: </label>1460-2393 
<br/><br/><label>Standard No.: </label>10.1093/qjmed/hcq017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Clopidogrel<br/>Drug Evaluation, Preclinical<br/>Hemorrhage--complications<br/>Humans<br/>Piperazines--antagonists & inhibitors<br/>Platelet Aggregation Inhibitors--pharmacokinetics<br/>Prasugrel Hydrochloride<br/>Purinergic P2 Receptor Antagonists<br/>Randomized Controlled Trials as Topic<br/>Receptors, Purinergic P2--therapeutic use<br/>Risk Factors<br/>Thiophenes--antagonists & inhibitors<br/>Ticlopidine--analogs & derivatives